stockrow
Friday 6 November 2026
Export KMDA’s income statement to Excel — free account
Kamada Ltd.
KMDA Healthcare Drug Manufacturers Specialty & Generic
Kamada Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $180.5 million, up 12.1% from fiscal 2024.
- Revenue
- +22.7%
- EPS
- +23.1%
- Free cash flow
- +165.7%
- Total debt
- −38.8%
Quarter to June 2026, against a year earlier
7.22
0.35
+5.09%
Follow KMDA
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
19.32 | 23.83 | 20.17 | 19.28 |
+8 more quarters Free account |
P/S ratio |
2.21 | 2.71 | 2.26 | 2.34 | |
P/FCF ratio |
16.15 | 30.09 | 26.00 | 22.27 | |
P/Operating CF |
23.52 | (1,691.74) | 53.79 | 39.21 | |
P/B ratio |
1.58 | 1.90 | 1.51 | 1.54 | |
Price to Tangible BV |
1.78 | 2.15 | 1.70 | 1.74 | |
EV/Sales |
1.94 | 2.42 | 1.95 | 2.05 | |
EV/EBITDA |
8.61 | 10.86 | 8.56 | 8.32 | |
EV/Operating CF |
10.39 | 17.13 | 13.82 | 12.63 | |
EV/FCF |
14.12 | 26.93 | 22.50 | 19.51 | |
Quick Ratio |
2.29 | 1.90 | 2.28 | 2.24 | |
Current Ratio |
4.06 | 3.33 | 4.07 | 4.03 | |
Net Debt/EBITDA |
(4.78) | (5.79) | (8.92) | (5.31) | |
Debt/Assets |
1.57% | 2.78% | 2.62% | 2.81% | |
Debt/Equity |
0.02 | 0.04 | 0.04 | 0.04 | |
Asset Turnover |
0.51 | 0.48 | 0.48 | 0.48 | |
Operating CF/Net income |
1.95 | (0.07) | 2.12 | 1.97 | |
Capex/Depreciation |
(0.54) | (0.25) | (0.73) | (0.95) | |
Interest Coverage |
25.63 | 36.98 | 13.71 | 35.37 | |
Research and Development Expense of Revenue |
4.01% | 4.82% | 6.48% | 5.61% | |
Selling, General and Administrative Expense of Revenue |
19.59% | 22.06% | 23.55% | 19.83% | |
Intangible Assets out of Total Assets |
0.08 | 0.08 | 0.08 | 0.08 | |
Share Based Compensation of Revenue |
1.31% | 1.77% | 1.03% | 0.25% | |
Graham Net Nets |
0.20 | 0.15 | 0.21 | 0.20 | |
Graham Number |
6.31 | 5.88 | 6.06 | 6.04 | |
Earnings Yield |
5.18% | 4.20% | 4.96% | 5.19% | |
Free Cash Flow Yield |
6.19% | 3.32% | 3.85% | 4.49% | |
Revenue per Share |
0.95 | 0.77 | 0.78 | 0.80 | |
Operating CF per Share |
0.31 | 0.00 | 0.13 | 0.18 | |
Capex per Share |
(0.04) | (0.02) | (0.05) | (0.06) | |
Free Cash Flow per Share |
0.28 | (0.02) | 0.08 | 0.12 | |
Cash per Share |
1.21 | 1.24 | 1.31 | 1.22 | |
Shareholders Equity per Share |
4.66 | 4.39 | 4.67 | 4.51 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
4.66 | 4.39 | 4.67 | 4.51 | |
Free Cash Flow |
15.96 | (1.26) | 4.79 | 6.83 | |
Working Capital |
150.42 | 139.46 | 145.68 | 144.90 | |
Capital Expenditures |
(2.11) | (0.97) | (2.77) | (3.59) | |
Net Current Asset Value |
85.97 | 75.60 | 83.44 | 80.76 | |
EV/EBIT |
13.35 | 17.35 | 13.42 | 12.89 | |
Capex to Sales |
0.04 | 0.02 | 0.06 | 0.08 | |
Price to Operating Income |
15.27 | 19.39 | 15.51 | 14.71 | |
| Other line items | |||||
Average Receivables |
38.89 | 37.27 | 29.88 | 28.09 | |
Average Payables |
37.28 | 45.52 | 36.38 | 28.60 | |
Average Inventory |
84.48 | 81.90 | 81.88 | 78.49 | |
Average Assets |
375.67 | 379.06 | 375.48 | 364.21 | |
Average Common Equity |
264.76 | 255.67 | 264.27 | 260.25 |
Columns are period end dates